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Non-ST elevation acute coronary syndrome (NSTEACS) occurs more frequently in older
patients with an increased occurrence of recurrent cardiac events following the index pre-
sentation. Telomeres are structures consisting of repeated DNA sequences as associated
shelterin proteins at the ends of chromosomes. We aim to determine whether telomere
length (TL) and telomerase activity (TA) predicted poor outcomes in older patients present-
ing with NSTEACS undergoing invasive care.
Method
Older patients undergoing invasive management for NSTEACS were recruited to the ICON-
1 biomarker study (NCT01933581). Peripheral blood mononuclear cells (PBMC) were
recovered on 153 patients. DNA was isolated and mean TL was measured by quantitative
PCR expressed as relative T (telomere repeat copy number) to S (single copy gene number)
ratio (T/S ratio), and a telomere repeat amplification assay was used to assess TA during
index presentation with NSTEACS. Primary clinical outcomes consisted of death, myocar-
dial infarction (MI), unplanned revascularisation, stroke and significant bleeding recorded at
1 year. TL and TA were divided into tertile groups for analysis. Cox proportional hazards
regression was performed. Ordinal regression was performed to evaluate the relationship
between TL and TA and traditional cardiovascular risk factors at baseline.
Results
298 patients were recruited in the ICON-1 study of which 153 had PBMC recovered. The
mean age was 81.0 ± 4.0 years (64% male). Mean telomere length T/S ratio was 0.47 ±
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0.25 and mean TA was 1.52 ± 0.61 units. The primary composite outcome occurred in 44
(28.8%) patients. There was no association between short TL or low TA and incidence of
the primary composite outcome (Hazard Ratio [HR] 1.50, 95% Confidence Interval [CI]
0.68–3.34, p = 0.32 and HR 1.33, 95% CI 0.52–3.36, p = 0.51 respectively).
Conclusion
TL and TA are not found to be associated with the incidence of adverse outcomes in older
patients presenting with NSTEACS undergoing invasive care.
Clinical trial registration
URL: https://www.clinicaltrials.gov Unique identifier: NCT01933581
Introduction
Older age is a well-known cardiovascular disease (CVD) risk factor, especially for coronary
artery disease (CAD)[1–3]. In a rapidly progressing ageing population, CAD prevalence, and
the related detrimental consequences, can only be expected to increase. Non ST-elevation
acute coronary syndromes (NSTEACS) are more common within the older population, with
the UK’s Myocardial Ischaemia National Audit Project (MINAP) data showing that 46% of all
non ST elevation myocardial infarction (NSTEMIs) suffered between 2006 and 2010 occurred
in patients aged�75 years old[4].
Telomeres are structures of tandemly repeated hexanucleotide TTAGGG sequences asso-
ciated with specific shelterin proteins at the end of eukaryotic chromosomes. They protect
internal chromosomal regions of DNA from degradation during cell division and gradually
shorten with each cycle due to the end replication problem as well as the sensitivity to oxida-
tive stress[5]. At a certain point the telomeres become too short to facilitate cell division,
resulting in cell senescence or apoptosis. Telomere length (TL) and telomerase activity (TA)
have been investigated regarding their possible applicability as biomarkers for age-related
chronic diseases, including CVD. Shorter TL has also been linked to an increased risk of
adverse events in patients with pre-existing CAD[6]. These studies have mostly been
restricted to younger patients, resulting in a paucity of research investigating this relation-
ship in older patients. Therefore we sought to investigate the association of TL and TA with




The Improve Cardiovascular Outcomes in high-risk older patients with acute coronary syn-
drome (ICON1) study is a multicentre prospective cohort study which aimed to develop a risk
score for high-risk older adults, the FRAIL-HEART score.[7–9] The study protocol has been
published previously[10]. The current study is a planned study as outlined in the the ICON1
study protocol[10]. Older patients (aged� 65 years old) presenting with NSTEACS with
planned invasive management were recruited from two tertiary cardiac care hospitals. The
study was carried out in accordance with the Declaration of Helsinki, and approved by the
regional ethics committee (NRES Committee North East–Sunderland 12/NE/0160). Partici-
pants gave written informed consent to take part in the study. The a priori primary outcome
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was created from data on death, acute coronary syndrome (ACS), unplanned revascularisa-
tion, stroke and BARC (Bleeding Academic Research Consortium)-defined bleeding (type 2 or
greater) at 1 year[11]. Follow-up was carried out in research clinics, and for patients unable to
attend telephone consultations were carried out. In participants where more than one compo-
nent of the composite outcome occurred, time-to-first-event was used. Detailed information
on baseline assessment had been previously published.[10] Frailty was assessed using Fried
Frailty Index, derived from the Cardiovascular Health Study with a score of 0 classed as robust,
1–2 as pre-frail and�3 as frail.[12]
Telomere and telomerase analysis
Peripheral blood mononuclear cells were isolated using leucosep tubes, and DNA extraction
performed using QIAamp1DNA mini kit (Qiagen). DNA concentration and quality was
ascertained using 260/280 nm spectrophotometry (NanoDropTM). Samples were diluted to 10
ng/ul prior to TL assay. Analysis of mean TL was performed using a quantitative, real-time
polymerase chain reaction-based assay, in quadruplicate using a 7900 HT Fast Real Time PCR
system (Applied Biosciences™). Comparison between signals from T (telomere repeat copy
number) to S (single copy gene number) were made, with the relative T/S ratio calculated. The
intra-assay coefficient of variation was 2.7%, and the inter-assay coefficient of variation was
5.1%. Telomerase activity was assessed using a telomere repeat amplification assay (Telo-
TAGGG™; Roche, Switzerland)[13] using 500ng lysate from PBMCs isolated in the same way
as above.
Statistical analysis
Statistical analyses were conducted with the use of SPSS software version 22 (SPSS Inc., Chi-
cago, IL, USA) and a two-tailed-test p value<0.05 was considered statistically significant.
Those variables classed as normally distributed were reported as mean ± standard deviation
(SD). Variables that were non-normally distributed were reported as median [interquartile
range (IQR)]. For TL analysis, data were split into three equal tertiles with patients categorized
into long TL (LTL, ratio�0.5), medium TL (MTL, ratio 0.3468–0.5), and short TL (STL,
ratio� 0.3467). TA data were also split into three equal tertiles for analysis: high TA (� 1.86
units), mid TA (1.32–1.86 units), and low TA (� 1.31 units).
Cox proportional hazard models were used to model the risk of incidence of the primary
composite end-point by tertile of TL and TA. Differences in baseline characteristics were
assessed between tertiles with one-way ANOVA for normally distributed continuous data,
Kruskal-Wallis testing for non-normally distributed continuous data, and chi-squared test
(χ2) or Fisher exact test (as appropriate with expected cell counts of <5) for categorical vari-
ables. Baseline characteristics did not vary between tertiles of TL or TA (see Table 1) there-
fore univariate cox proportional hazard models were used. In addition, adjusted Cox
proportional hazards regression models were also used, adjusting for age, gender and frailty.
Kaplan-Meier survival analysis was performed to compare event-free survival from inci-
dence of the primary composite outcome between tertiles of TL and TA, probed with the
Log-rank test. TL and TA was also assessed as continuous variables (S1–S3 Figs). The mean
TL and TA subjects with composite events were compared to subjects without composite
events with Wilcoxon rank sum test. In addition TL and TA was also classified into two
groups based on receiver operating characteristic curve to determine the best cut-off.
Details can be found in S1 Table.
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Table 1. Baseline characteristics.








Age, years (SD) 80.8 (4.1) 80.2 (3.4) 80.7 (4.4) 81.6 (3.9) 0.39
Female, n (%) 47 (34.8) 20 (46.5) 12 (25.5) 15 (33.3) 0.49
NSTEMI, n (%) 246 (82.0) 31 (72.1) 39 (83.0) 36 (80.0) 0.43
UA, n (%) 54 (18.0) 12 (27.9) 8 (17.0) 9 (20.0) 0.44
Clinical Measures
BMI, kg m-2 (SD) 26.7 (4.2) 26.7 (4.7) 26.7 (3.9) 26.7 (4.5) 0.95
Systolic BP, mmHg (SD) 145.2 (26.5) 147.1 (19.9) 145.5 (26.5) 142.8 (32.3) 0.80
NYHA functional class, n (%):
1—no limitation of activity 51 (38.1) 16 (38.1) 21 (44.7) 14 (31.1) 0.18
2—slight limitation of activity 50 (37.3) 18 (42.9) 15 (31.9) 17 (37.8)
3—marked limitation of activity 32 (23.9) 3 (9.1) 21(31.3) 8 (23.5)
4—unable to carry out activity 1 (0.7) 1 (2.4) 0 (0.0) 0 (0.0)
GRACE Score, points (SD) 130.2 (18.5) 130.2 (17.1) 129.8 (18.5) 130.7 (20.2) 0.97
Medical History
Diabetes, n (%) 30 (22.2) 13 (30.2) 7 (14.9) 10 (22.2) 0.64
Hypertension, n (%) 92 (68.1) 25 (58.1) 35 (74.5) 32 (71.1) 0.30
Hyperlipidaemia, n (%) 69 (51.1) 23 (53.5) 25 (53.2) 21 (46.7) 0.53
Renal impairment, n (%) 33 (24.4) 9 (20.9) 15 (31.9) 9 (20.0) 0.39
Previous MI, n (%) 37 (27.4) 12 (27.9) 11 (23.4) 14 (31.1) 0.47
Previous angina, n (%) 57 (42.2) 18 (41.9) 21 (44.7) 18 (40.0) 0.85
Previous PCI, n (%) 24 (17.8) 7 (16.3) 11 (23.4) 6 (13.3) 0.86
Previous CABG, n (%) 8 (5.9) 4 (9.3) 1 (2.1) 3 (6.7) 0.07
HF, n (%) 10 (7.4) 3 (7.0) 4 (8.5) 3 (6.7) 0.82
AF, n (%) 19 (14.1) 4 (9.3) 8 (17.0) 7 (15.6) 0.36
PVD, n (%) 13 (9.6) 4 (9.3) 4 (8.5) 5 (11.1) 0.86
Previous TIA/Stroke, n (%) 19 (14.1) 3 (7.0) 9 (19.1) 7 (15.6) 0.63
Osteoarthritis, n (%) 4 (3.0) 1 (2.3) 1 (2.1) 2 (4.4) 0.46
Peptic ulcer disease, n (%) 6 (4.4) 2 (4.7) 1 (2.1) 3 (6.7) 0.85
COPD, n (%) 23 (17.0) 6 (14.0) 11 (23.4) 6 (13.3) 0.51
Malignancy, n (%) 11 (8.1) 3 (7.0) 6 (12.8) 2 (4.4) 0.43
Bleeding problems, n (%) 4 (3.0) 0 (0.0) 2 (4.3) 2 (4.4) 0.47
Anaemia, n (%) 11 (8.1) 2 (4.7) 5 (10.6) 4 (8.9) 0.45
Smoking Status
Current smoker, n (%) 9 (6.8) 1 (2.4) 4 (8.5) 4 (8.9) 0.36
Ex-smoker, n (%) 66 (49.6) 20 (48.8) 25 (53.2) 21 (46.7) 0.93
Never-smoker, n (%) 58 (43.6) 20 (48.8) 18 (38.3) 20 (44.4) 0.94
Frailty Indices
Fried index components
Shrinking criterion, n (%) 24 (17.8) 4 (9.5) 10 (21.3) 10 (22.2) 0.36
Low physical endurance, n (%) 33 (24.6) 6 (14.3) 15 (31.9) 12 (26.7) 0.14
Low physical activity, n (%) 35 (25.9) 6 (14.3) 15 (31.9) 14 (31.1) 0.34
Weakness, n (%) 83 (62.4) 25 (59.5) 28 (60.9) 30 (66.7) 0.80
Slow walking speed, n (%) 23 (17.0) 7 (16.7) 7 (15.6) 9 (20.0) 0.85
Rockwood score, n (%)
1 − 2 46 (34.1) 18 (41.9) 13 (27.7) 15 (33.3) 0.28
(Continued)
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Results
Baseline characteristics
A total of 153 patients had PBMC samples recovered as part of the ICON1 biomarker sub-
study and of these samples, 135 patients had appropriate samples for TL analysis and 67 sam-
ples were analysed for TA. Patient baseline characteristics are illustrated in Table 1. There was
no significant difference in baseline characteristics between tertiles of TL.
The mean age of participants was 81.0 ± 4.0 years and 64.0% were male, with 87.5% of par-
ticipants classed as pre-frail or frail. The mean cohort telomere length was 0.47 ± 0.25 and was
split into tertiles for analysis: LTL (n = 43, mean 0.74 ± 0.27), MTL (n = 47, mean 0.42 ± 0.05)
and STL (n = 45, mean 0.25 ± 0.06). The mean cohort TA was 1.52 ± 0.61 units and split into
tertiles for analysis: high TA (n = 23, 2.09 ± 0.24), mid TA (n = 22, 1.61 ± 0.15) and low TA
(n = 22, 0.83 ± 0.48).
Of the 153 patients in the study, 111 patients (82.2%) underwent PCI. As demonstrated in
Table 2, there were no significant differences in the coronary arteries affected, number of
stents used or medical therapy on discharge between tertiles of TL.
Telomere length, telomerase activity and adverse outcomes
Incidence of the primary composite outcome at 1 year is detailed in Table 3. The primary
composite outcome occurred in 44 patients (28.8%). There was no significant difference in the
incidence of the primary composite outcome between tertiles of TL (p = 0.57) or TA
(p = 0.62).
Table 1. (Continued)







3 − 4 72 (53.3) 22 (51.2) 27 (57.4) 23 (51.1)
5 − 7 17 (12.6) 3 (7.0) 7 (14.9) 7 (15.6)
Quality of Life and Co-morbidity
MoCA, points (SD) 25.1 (3.4) 25.5 (2.5) 25.4 (3.6) 24.2 (3.8) 0.29
SF-36 PCS, points (SD) 36.6 (11.3) 35.4 (8.9) 37.6 (12.2) 35.8 (11.7) 0.98
SF-36 MCS, points (SD) 49.6 (10.2) 47.6 (10.7) 50.0 (10.2) 50.9 (9.8) 0.91
Health state, % (SD) 63.7 (19.4) 59.8 (19.8) 66.2 (19.7) 62.3 (18.0) 0.88
Charlson index, points (SD) 5.3 (1.7) 5.4 (1.5) 5.1 (1.8) 5.6 (1.9) 0.63
Blood results
Haemoglobin, g L-1 (SD) 12.9 (1.9) 13.0 (1.6) 13.2 (1.7) 12.4 (2.5) 0.88
Creatinine, μmol L-1 (SD) 103.5 (32.7) 106.7 (39.0) 99.5 (28.4) 108.3 (34.1) 0.60
Total cholesterol, mmol L-1 (SD) 4.3 (1.3) 4.5 (1.5) 4.3 (1.3) 3.9 (0.8) 0.71
hsCRP, mg L-1 (SD) 12.3 (37.6) 7.5 (6.7) 15.8 (50.9) 9.5 (16.1) 0.29
Troponin T, ng L-1 (SD) 511.8 (983.7) 606.0 (1159.1) 403.6 (860.9) 636.8 (1035.8) 0.55
eGFR, mL min-1 1.73 m-2 (SD) 54.5 (19.5) 54.3 (21.2) 56.2 (18.1) 51.2 (20.5) 0.71
Abbreviations: AF—atrial fibrillation, BMI—body mass index, BP—blood pressure, CABG—coronary artery bypass graft, COPD—chronic obstructive pulmonary
disease, EQ—EuroQol form, GRACE—Global Registry of Acute Coronary Events, HF—heart failure, IDAOPI—Income Deprivation Affecting Older People Index,
IMD—Index of Multiple Deprivation, IQR—interquartile range, LTL- long telomere length, MTL- medium telomere length, STL-short telomere length, MCS—mental
component summary, MI—myocardial infarction, MoCA—Montreal Cognitive Assessment, NYHA—New York Heart Association class, PCI—percutaneous coronary
intervention, PCS—physical component summary, PVD—peripheral vascular disease, SD—standard deviation, SF-36—short form 36, TIA—transient ischaemic attack,
eGFR—estimated glomerular filtration rate, hsCRP—C-reactive protein
https://doi.org/10.1371/journal.pone.0227616.t001
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Cox proportional hazard models between tertiles of TL and TA and the incidence of the pri-
mary composite outcome are detailed in Table 4. There was an increased hazard of the pri-
mary composite outcome in patients with a MTL (hazard ratio HR 1.28, 95% Confidence
Interval CI 0.56–2.91, p = 0.56) and STL (HR 1.50, 95% CI 0.68–3.34, p = 0.32) when compared
to the reference patients with a LTL, however this was not statistically significant. There was
no significant difference between TA and the incidence of the primary composite outcome in
patients with a mid TA (HR 0.90, 95% CI 0.94–2.60, p = 0.89) and low TA (HR 1.33, 95% CI
0.52–3.36, p = 0.51). The results are consistent after adjusting for age, gender and frailty in the
Table 2. Procedural charactersitics.








1, n (%) 115 (81.2) 35 (81.4) 41 (87.2) 39 (86.7) 0.79
2, n (%) 16 (11.8) 7 (16.3) 4 (8.5) 5 (11.1)
3, n (%) 4 (0.03) 1 (2.3) 2 (4.3) 1 (2.2)
PCI, n (%) 111 (82.2) 34 (79.1) 40 (85.1) 37 (82.2) 0.76
Coronary arteries affected
One vessel disease, n (%) 85 (63.0) 26 (60.5) 29 (61.7) 30 (66.7) 0.81
Multi-vessel disease, n (%) 27 (20.0) 9 (20.9) 11 (23.4) 7 (15.6) 0.63
LMS, n (%) 4 (3.0) 0 (0.0) 2 (4.3) 2 (4.4) 0.38
LAD, n (%) 64 (47.4) 19 (44.2) 23 (48.9) 22 (48.9) 0.88
LCx, n (%) 34 (25.2) 9 (20.9) 12 (25.5) 13 (28.9) 0.69
RCA, n (%) 39 (28.9) 14 (32.6) 15 (31.9) 10 (22.2) 0.48
Number of stents used
0, n (%) 27 (20.0) 11 (25.6) 7 (14.9) 9 (20.0) 0.78
1, n (%) 55 (40.7) 14 (32.6) 22 (46.8) 19 (42.2)
2, n (%) 30 (22.2) 11 (25.6) 10 (21.3) 9 (20.0)
3, n (%) 13 (9.6) 6 (14.0) 4 (8.5) 3 (6.7)
4, n (%) 7 (5.2) 1 (2.3) 3 (6.4) 3 (6.7)
5, n (%) 2 (1.5) 0 (0.0) 1 (2.1) 1 (2.2)
6, n (%) 1 (0.7) 0 (0.0) 0 (0.0) 1 (2.2)
Medical therapy on discharge
Aspirin, n (%) 132 (97.8) 41 (95.3) 46 (97.9) 45 (100.0) 0.33
Clopidogrel, n (%) 78 (57.8) 25 (58.1) 26 (55.3) 27 (60.0) 0.90
Prasugrel, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0
Ticagrelor, n (%) 52 (38.5) 16 (37.2) 19 (40.4) 17 (37.8) 0.94
Statin, n (%) 126 (93.3) 42 (97.7) 42 (89.4) 42 (93.3) 0.98
ACEi/A2RB, n (%) 117 (86.7) 36 (83.7) 42 (89.4) 39 (86.7) 0.73
BB, n (%) 113 (83.7) 37 (86.0) 42 (89.4) 34 (75.6) 0.18
CCB, n (%) 42 (31.1) 12 (27.9) 15 (31.9) 15 (33.3) 0.85
ISMN, n (%) 42 (31.1) 15 (34.9) 16 (34.0) 11 (24.4) 0.49
Nicorandil, n (%) 20 (14.8) 8 (18.6) 7 (14.9) 5 (11.1) 0.61
PPI, n (%) 63 (46.7) 20 (46.5) 16 (34.0) 27 (60.0) 0.055
Warfarin, n (%) 10 (7.4) 2 (4.7) 4 (8.5) 4 (8.9) 0.70
DOAC, n (%) 5 (3.7) 2 (4.7) 2 (4.3) 1 (2.2) 0.80
Abbreviations: ACEi/A2RB–angiotensin converter inhibitor/angiotensin 2 receptor blocker, BB–beta blocker, CCB–calcium channel blocker, DOAC—direct acting oral
anticoagulants, ISMN–isosorbide mononitrate, LAD–left anterior desceding coronary artery disease, LCx–left coronary artery disease, LMS–left main stem coronary
artery disease, LTL- long telomere length, MTL- medium telomere length, STL-short telomere length, PPI–proton pump inhibitor, RCA–right coronary artery disease
https://doi.org/10.1371/journal.pone.0227616.t002
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analysis model. Kaplan-Meier survival curves for TL (Fig 1) and TA (Fig 2) show no difference
between groups for both TL (p = 0.61) and TA (p = 0.74). These results are consistent when
primary outcome were analysed without BARC. See S2 Table.
Discussion
This is the first study to examine the association of TL and TA with adverse clinical outcomes
in older patients with NSTEACS undergoing an invasive treatment strategy. Neither TL nor
TA were found to be associated with adverse outcomes in older patients with NSTEACS.
Ischaemic heart disease (IHD) is the leading cause of death worldwide[14] and importantly,
the demographic of the condition is changing, with increasing frequency of older patients pre-
senting with IHD. Studies have also shown that advancing age is associated with increased risk
of mortality following cardiovascular events[15]. The increase of IHD burden in older patients,
Table 3. Outcome measures.







Composite, n (%) 38 (28.1) 10 (23.3) 13 (27.7) 15 (33.3) 0.57
Death, n (%) 6 (4.4) 1 (2.3) 2 (4.2) 3 (6.7) 0.61
Myocardial infarction, n (%) 12 (8.9) 5 (11.6) 4 (8.4) 3 (6.7) 0.71
Unplanned revascularisation, n (%) 6 (4.4) 4 (9.3) 0 2 (4.4) 0.10
Stroke, n (%) 2 (1.5) 1 (2.3) 0 1 (2.2) 0.58
Significant bleeding, n (%) 21 (15.6) 4 (9.3) 9 (19.1) 8 (17.8) 0.54
All-cause re-hospitalisation, n (%) 69 (51.1) 21 (48.8) 25 (53.2) 23 (51.1) 0.92
LTL long telomere length, MTL medium telomere length, STL short telomere length.
https://doi.org/10.1371/journal.pone.0227616.t003
Table 4. Telomere length and telomerase activity as predictors of the primary composite outcome.
Hazard ratio 95% confidence interval p-value
Model 1
TL�
MTL 1.28 0.56–2.91 0.56
STL 1.50 0.68–3.34 0.32
TA†
Mid 0.90 0.94–2.60 0.89
Low 1.33 0.52–3.36 0.51
Model 2
TL�
MTL 1.49 0.64–3.45 0.35
STL 1.58 0.71–3.55 0.26
TA†
Mid 1.04 0.37–2.92 0.94
Low 1.18 0.46–3.06 0.73
Univariate (model 1) and multivariate (model 2; adjusted for age, gender and frailty) Cox regression analysis
preformed for combined and primary outcomes alone using telomere length and telomerase activity as predictors.
Both predictors were divided into tertiles for analysis.
� LTL used as reference.
† High used as reference. MTL- medium telomere length, STL-short telomere length and TA-telomerase activity.
https://doi.org/10.1371/journal.pone.0227616.t004
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Fig 1. Telomere length and cumulative event rates. Cumulative event-free survival from the composite primary end-
point by tertile of telomere length. LTL� 0.5 T/S ratio, MTL 0.3468 to 0.5 T/S ratio and STL� 0.3467 T/S ratio. P
value from the Log-rank test. LTL, long telomere length; MTL; medium telomere length and STL; short telomere
length.
https://doi.org/10.1371/journal.pone.0227616.g001
Fig 2. Telomerase activity and cumulative event rates. Cumulative event-free survival from the composite primary
end-point by tertile of telomerase activity. High telomerase activity denotes�1.86 units, mid telomerase activity 1.32 to
1.86 units, and low telomerase activity�1.31 units. P value from the Log-rank test.
https://doi.org/10.1371/journal.pone.0227616.g002
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together with the increased risk of poorer outcome, drives a need for markers which could
guide the management of ACS in this group of patients.
Telomeres are protective structures at the end of chromosomes which act to stabilise
genome integrity, and have been implicated as a marker of biological age and age-related dis-
eases. The length of telomere shortens with subsequent cell division, and this shortening is
accelerated by inflammation and oxidative stress, processes implicated in the pathophysiology
of IHD. To prevent telomere shortening to a critical length, in cells such as germ cells and
stem cells, telomerase activity is high to maintain and elongate telomeres. In most somatic
cells, telomerase activity is absent or low, but a mouse study has suggested that telomerase
might play a role in regulating tissue repair in cardiomyocytes and endothelial progenitor cells
[16].
Previous studies evaluating the association of telomere lenth and telomerase activity on
clinical outcomes in different populations have shown varied results[17–25]. In a prospective
WOSCOPS study of 484 participants with a mean age of 55 years, participants in the middle
and the lowest tertiles of telomere length were more at risk of developing a coronary heart dis-
ease event than were individuals in the highest tertile (odds ratio [OR] for coronary heart dis-
ease: 1.51, 95% CI 1.15–1.98; p = 0.0029 in the middle tertile; 1.44, 1.10–1.90, p = 0.0090 in the
lowest)[26]. In a meta-analysis of prospective and retrospective studies with 5566 participants
with CHD, the pooled relative risk for CHD of shortest versus longest tertile telomere length
was 1.54 (95% CI 1.30 to 1.83)[27]. Moreover, in a previous study of 170 patients with stable
angina or acute coronary syndrome and using virtual histology intravascular ultrasound, it
was shown that shorter TL was associated with a high risk of unstable plaques (calcified thin-
capped fibroatheroma), with an OR of 1.24 (95% CI 1.01 to 1.53)[28]. Our results contradict
the previous literature, a finding which may be partly explained by differences in the study
design, methodology and patient cohort. Our study population is generally older, underwent
invasive management, and we specifically examined NSTEACS as this is the predominant
ACS phenotype in this age group. This differs to previous research, which was in a majority
performed in a younger cohort and included all ACS types.
Epel and colleagues[25] found that the rate of telomere shortening was predictive of mortal-
ity from cardiovascular disease in elderly men, suggesting that low telomerase activity contrib-
ute to cardiovascular risk. However, our study found that telomerase activity was not
associated with adverse outcomes following invasive management of NSTEACS. This may
partly be explained by the difference of study populations. Epel et al. recruited healthy older
volunteers prior to cardiovascular event, compared to the patients presenting with NSTEACS
in the current study. Hence, this study focused on telomere length in those whom already
developed coronary artery disease. The results together would suggest that dependent upon
the cumulative oxidative stress and inflammatory burden, telomere attrition may play a differ-
ent role in the process of atherosclerosis in older patients. Consistent with this hypothesis,
Perez-Rivera et al[29]. found worse prognosis with short telomere length in middle aged men
with ACS but not in older patients.
It has been speculated that telomere attrition and the resulting cell senescence may act as a
mechanism for restricting atheromas[30]. Indeed, this is consistent with our study result show-
ing low telomerase activity was not associated with adverse outcomes in older patients. Fur-
thermore, telomerase-deficient mice TERC-/- ApoE-/- had fewer atherosclerotic lesions
compared to TERC+/+ ApoE-/-[31], and Willeit et al[32] showed that TL was a risk predictor
for myocardial infarction, but not for de novo stable angina and intermittent claudication.
Therefore, telomere attrition causes senescence and apoptosis, but may have process-specific
effect on atherosclerosis[30].
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Recently Werner and colleagues found that specific exercise modalities were associated
with increased telomere length and telomerase activity[33].This raises the interesting possibil-
ity that the benefits of exercise in reducing and preventing frailty in the older population may
act through regulating cellular senescence. The current study found no association between
telomere length and frailty, which is consistent with the results demonstrated by Brault et al. in
older adults with cardiac disease[34]. These results suggest that frailty may be the consequence
of repeated physiological stress induced premature cellular senescence in addition to progres-
sive telomere shortening. It would be interesting to investigate the effect of exercise on telo-
mere length and frailty in older adults with established cardiac disease.
Limitations
The limitation of this study is the relatively small number of adverse outcomes observed in the
1 year follow-up, therefore these results should be interpreted with caution. Recruiting older
patients to clinical research is very challenging[35, 36]. Very few studies have evaluated older
patients with NSTEACS. A lot of factors and therapy that show positive correlation in younger
patients, don’t quite show this in older patients. Given the growth of older patients with coro-
nary disease, it is important the cardiovascular community are aware of such differences in the
best care of older patients. Our study with the sample size included with detailed statistical
analysis provides important information regarding these patients.
Larger follow-up studies would be required to evaluate the true value of TL and TA as pre-
dictors in this setting. A further limitation is that we have not considered leukocyte subpopula-
tions distributions, a factor that can determine the measurements of both TL and TA TL[37]
as well as the association of both parametres to cardiac dysfunction[38].
Conclusion
The present study found TL and TA were not associated with adverse outcomes in older
patients presenting with NSTEACS.
Supporting information
S1 Fig. Scatter plot of telomere length vs. age. Scatter plot analysis of TL with age yields a
non statstiacally significant increasing regression line in aged 75–80 (Spearman’s correlation
coefficient, rs = 0.052, p = 0.66) and a decreasing regression line in aged> 80 (rs = -0.11,
p = 0.34).
(TIF)
S2 Fig. Scatter plot of telomerase activity vs. age. Scatter plot analysis of TA with age yields a
non-statistically significant decreasing regression line (Spearman’s correlation coefficient, rs =
-0.22, p = 0.071).
(TIF)
S3 Fig. Boxplots of telomere length for subjects with primary outcomes vs without primary
outcomes. A Wilcoxon signed–rank test showed that telomere lengths did not elicit a signifi-
cant change for subjects with primary outcomes compared to subjects without composite
events (Z = -0.655, p = 0.071).
(TIF)
S4 Fig. Boxplots of telomerase activity for subjects with primary outcomes vs without pri-
mary outcomes. A Wilcoxon signed–rank test showed that telomerase activity did not elicit a
significant change for subjects with primary outcomes compared to subjects without
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composite events (Z = -1.274, p = 0.20).
(TIF)
S1 Table. Telomere length and telomerase activity classified by ROC, as predictors of the
primary composite outcome. Cox regression analysis preformed for combined and primary
outcomes alone using telomere length and telomerase activity as predictors. Both predictors
were divided into two groups for analysis based upon area under curve (ROC). For TL, area
under curve was 0.57 (p = 0.17). The best cutoff was 0.61 with sensitivity of 87% and specificity
of 80%. With this cut-off, 111 participants had STL (82.2%) and 24 had LTL (17.8%). The area
under curve was also measured for TA at 0.54 (p = 0.57), with cut-off of 1.88 (sensitivity of
80% and specificity of 64%). 47 (70.1%) participants classified as low TA and 20 (29.9) as high
TA. � LTL used as reference. † High used as reference. TL- telomere length and TA-telomerase
activity.
(DOCX)
S2 Table. Telomere length and telomerase activity as predictors of the primary composite
outcome without major bleeding. Cox regression analysis preformed for combined outcomes
without major bleeding using telomere length and telomerase activity as predictors. Both pre-
dictors were divided into tertiles for analysis. � LTL used as reference. † High used as reference.
MTL- medium telomere length, STL-short telomere length and TA-telomerase activity.
(DOCX)
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